Skip to content

Clinical trials

Colorectal Neoplasms trials in China with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Colorectal Neoplasms Phase: Not applicable Country / region: China Clear all

135 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20101
20111
20122
20131
20141
20151
20165
20175
20183
201911
202010
20219
20229
202319
202425
202518
202614

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting41
Unknown status39
Completed23
Not yet recruiting14
Active, not recruiting6
Withdrawn4
Terminated3
Enrolling by invitation3
Suspended2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fudan University9
Sixth Affiliated Hospital, Sun Yat-sen University6
Sun Yat-sen University5
Nanchong Central Hospital4
Ruijin Hospital4
The First Affiliated Hospital of Nanchang University4
West China Hospital4
Zhejiang University4
Chinese University of Hong Kong3
Nanfang Hospital, Southern Medical University3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Colorectal Neoplasms135
Stomach Neoplasms8
Colonic Polyps5
Lung Neoplasms5
Breast Neoplasms4
Colonic Neoplasms4
Esophageal Neoplasms4
Liver Neoplasms4
Rectal Neoplasms4
Adenoma3

Trials

Showing 1 to 25 of 135. Each trial links to its page on Pharma Observatory.

35 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.